Menu Search
Equities

Mauna Kea Technologies SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0P5I:LSE

Mauna Kea Technologies SA

Actions
  • Price (EUR)0.124
  • Today's Change-0.007 / -5.49%
  • Shares traded88.00
  • 1 Year change-27.49%
  • Beta1.0459
Data delayed at least 20 minutes, as of Feb 12 2026 08:44 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mauna Kea Technologies SA formerly Mauna Kea Technologies SAS is a France-based medical device manufacturing company. The Company specializes in designing, developing, and selling optical biopsy devices and tools. Its products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. It provides Cellvizio product that is used by medical specialties and is revolutionizing the way physicians diagnose and treat patients making a transformative change in medicine. Its real-time in vivo cellular imaging platform, that delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time.

  • Revenue in EUR (TTM)7.48m
  • Net income in EUR-10.39m
  • Incorporated2000
  • Employees61.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.